Offering Psychedelic Treatments Before Assisted Dying for Psychiatric Conditions
Christopher Poppe, Jan Christoph Bublitz, Dimitris Repantis
JAMA Psychiatry August 1, 2025 DOI: 10.1001/jamapsychiatry.2025.1457 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Population | Persons with psychiatric conditions considering physician-assisted death |
| Key points | Psychedelic treatment may serve as life-preserving care for psychiatric patients before physician-assisted death. |
Abstract
This Viewpoint describes the benefits of providing psychedelic treatment to persons with psychiatric conditions as life-preserving care before physician-assisted death.
Citations in the library
Cited by 6
- Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop. Healthcare September 12, 2025
- Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report Palliative & Supportive Care 2025
- Last resort: the ethical obligation to offer ketamine in psychiatric euthanasia and assisted suicide Journal of Medical Ethics August 5, 2026
- Perceptions of Australasian palliative care physicians regarding the safety and efficacy of psychedelic medicines: An exploratory mixed-methods study Psychedelics April 4, 2026
- Market approval and the right to health: a human rights perspective on MDMA-assisted therapy JME Practical Bioethics April 1, 2026
and 1 more in the library
Cites 5
- Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research May 1, 2024
- Psychiatric risks for worsened mental health after psychedelic use. Journal of Psychopharmacology March 4, 2024
- Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial American Journal of Psychiatry 2025
- Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis. American Journal of Geriatric Psychiatry November 1, 2022
- Expanded access to psychedelic treatments: comparing American and Canadian policies. General Psychiatry February 19, 2025